Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma (NCT06372496)
A Phase 4, 52-week (Primary Analysis at 24-weeks), Randomized, Stratified, Open-label, Active-controlled, Parallel-group, Effectiveness Study, Comparing FF/UMEC/VI With Non-ellipta Usual Care (ICS/LABA) in Adult Participants With Uncontrolled Asthma
🩺 Plain-English Summary (8th-Grade Level)
The goal of this study is to assess and compare the effectiveness of fluticasone furoate/umeclidinium bromide/vilanterol trifenatate (FF/UMEC/VI) with inhaled corticosteroids/long-acting beta-2 agonists (ICS/LABA) in adult participants with uncontrolled asthma
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Centreville, Alabama
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (117 Sites)
Showing the first 25 of 117 sites.
- GSK Investigational Site — Centreville, Alabama
- GSK Investigational Site — Little Rock, Arkansas
- GSK Investigational Site — Newport Beach, California
- GSK Investigational Site — Newark, Delaware
- GSK Investigational Site — Clearwater, Florida
- GSK Investigational Site — Florida City, Florida
- GSK Investigational Site — Miami, Florida
- GSK Investigational Site — Miami, Florida
- GSK Investigational Site — Miami, Florida
- GSK Investigational Site — Miami, Florida
- GSK Investigational Site — North Miami Beach, Florida
- GSK Investigational Site — Palm Springs, Florida
- GSK Investigational Site — Port Charlotte, Florida
- GSK Investigational Site — Tallahassee, Florida
- GSK Investigational Site — Normal, Illinois
- GSK Investigational Site — New Orleans, Louisiana
- GSK Investigational Site — Bangor, Maine
- GSK Investigational Site — Detroit, Michigan
- GSK Investigational Site — Warren, Michigan
- GSK Investigational Site — Missoula, Montana
- GSK Investigational Site — Papillion, Nebraska
- GSK Investigational Site — Brick, New Jersey
- GSK Investigational Site — Linwood, New Jersey
- GSK Investigational Site — New Windsor, New York
- GSK Investigational Site — Asheville, North Carolina
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Asthma
- Investigating Dupilumab's Effect in Asthma by Genotype — Boston, Massachusetts
- Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma — Bakersfield, California
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma — Saraland, Alabama
- Reduce IDentified UNcontrolled Asthma — San Diego, California
- A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma — Little Rock, Arkansas
- REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study — La Jolla, California
Explore by condition: All Asthma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.